Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 182 results.
LastUpdate Updated on 17/11/2026 [08:29:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
previousPage Results 75 to 100 of 182 nextPage  

METHODS AND SYSTEMS FOR CONTROLLING AN INFUSION PUMP

Publication No.:  US20260295159A1 01/10/2026
Applicant: 
DEKA PRODUCTS LP [US]
DEKA Products Limited Partnership
US_20260295159_A1

Absstract of: US20260295159A1

A system for pairing a controller and an infusion pump is disclosed. The system includes an infusion pump, a controller device and a user interface residing on both the infusion pump and the controller. The user interface includes a pairing mode for enabling wireless communication between the infusion pump and the controller device, wherein the user interface requires both the infusion pump and the controller to be in the pairing mode simultaneously. Also, a method of changing a power source in an infusion pump is disclosed. The method includes placing the infusion pump in idle mode wherein the infusion pump stops delivery. Removing the first power source from the infusion pump. Replacing the first power source with a second power source in the infusion pump, and maintaining the insulin on board during the changing of the first power source with the second power source.

CELL PRESERVATION SOLUTION AND CELL PRESERVATION METHOD

Publication No.:  US20260297540A1 01/10/2026
Applicant: 
UNIDT SHANGHAI CO LTD [CN]
UNIDT (Shanghai) Co., Ltd.
US_20260297540_A1

Absstract of: US20260297540A1

0000 One aspect of the embodiments relates to a cell preservation solution, comprising: 20 mM~50 mM of sucrose; 20 mM~50 mM of mannitol, 10 mM~50 mM of lactobionic acid, 5 mM~20 mM of glucose, 1 mM~3 mM of adenosine, 1 mM~5 mM of reduced glutathione, 1 mM~2 mM of dextran-40, 10 mM~30 mM of potassium dihydrogen phosphate, 10 mM~30 mM of potassium carbonate, 10 mM~30 mM of potassium chloride, 5 mM~30 mM of sodium chloride, 10 mM~60 mM of sodium hydroxide, 10 mM~60 mM of potassium hydroxide, 0 mM~20 mM of vitamin E, 0 mM~25 mM of 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid, and 0%~10% dimethyl sulfoxide. Another aspect of the embodiments relates to a cell preservation method, which uses the cell preservation solutions described in the present application to store cells.

MEALTIME DELIVERY OF CORRECTION BOLUSES

Publication No.:  US20260295161A1 01/10/2026
Applicant: 
MEDTRONIC MINIMED INC [US]
Medtronic MiniMed, Inc.
US_20260295161_A1

Absstract of: US20260295161A1

Disclosed herein are techniques related to delivery of correction boluses. In some embodiments, the techniques involve obtaining data indicative of an ongoing glycemic response to a meal. The data includes glucose concentration measurements evaluated in combination with one or more insulin concentration values. The techniques further include causing delivery of one or more correction doses to at least partially counteract the ongoing glycemic response to the meal. The one or more correction doses are delivered instead of or in addition to a meal bolus delivered for the meal.

SYSTEM AND METHOD OF MODIFYING USER PROFILE IN AUTOMATED INSULIN DELIVERY

Publication No.:  US20260295160A1 01/10/2026
Applicant: 
TANDEM DIABETES CARE INC [US]
Tandem Diabetes Care, Inc.
US_20260295160_A1

Absstract of: US20260295160A1

Disclosed herein are systems and methods for automated insulin delivery that provide for adaptive closed loop control that can modify the stored basal profile used by the closed loop algorithm to better reflect the user's actual needs. Actual delivery rates calculated by the closed loop algorithm can be compared to the user's stored profile. If the differences between the actual delivery rates and the stored profile are statistically significant, the stored profile can be modified.

METHOD FOR STRUCTURING AND CLASSIFICATION OF CONTINUOUS GLUCOSE MONITORING (CGM) PROFILES

Publication No.:  US20260294352A1 01/10/2026
Applicant: 
UNIV OF VIRGINIA PATENT FOUNDATION [US]
UNIVERSITY OF VIRGINIA PATENT FOUNDATION
US_20260294352_A1

Absstract of: US20260294352A1

0000 Embodiment relate to a system for developing a model to classify continuous glucose monitoring (CGM) data. The system includes a processor and computer memory having instructions stored thereon that when executed will cause the processor to determine whether two CGM profiles match based on a similarity of shapes of the two CGM profiles, each CGM profile including a data set of CGM measurements. The processor designates two matching CGM profiles as a CGM profile pair. The processor transforms the CGM profile pair into a motif. The processor labels the motif as a labelled motif based on a clinical characteristic. The processor recursively repeats the determine, designate and transform steps of a CGM profile pairing process until a finite set of motifs is created, which includes the labelled motif as a classified data point. The processor monitor, analyzes, or influences a concentration of glucose levels in a fluid.

METHODS OF DETERMINING GLUCOSE HYPOMETABOLISM-INDUCED ENERGY CRISIS AND TREATMENTS THEREOF

Publication No.:  WO2026207251A1 01/10/2026
Applicant: 
SENOVIA BIOSCIENCES LLC [US]
ANDERSON II JOEL R [US]
SENOVIA BIOSCIENCES LLC
ANDERSON, II, Joel R.
WO_2026207251_A1

Absstract of: WO2026207251A1

The present disclosure provides systems, methods, compositions, and algorithms for treating a subject diagnosed with a glucose hypometabolic disorder (e.g., Alzheimer's disease, Parkinson's disease, or heart failure).

BIOINTERFACE LAYER FOR ANALYTE SENSORS

Publication No.:  EP4814115A2 30/09/2026
Applicant: 
DEXCOM INC [US]
DexCom, Inc.
EP_4814115_A2

Absstract of: EP4814115A2

Disclosed are devices for determining an analyte concentration (e.g., glucose). The devices comprise a sensor configured to generate a signal associated with a concentration of an analyte and a sensing membrane located over the sensor. The sensing membrane comprises a biointerface layer which interfaces with a biological fluid containing the analyte to be measured. The biointerface layer comprises a biointerface polymer, wherein the biointerface polymer comprises polyurethane and/or polyurea segments and one or more zwitterionic repeating units. The biointerface layer increases sensor longevity and decrease sensor inaccuracy by inhibiting accumulation of cells, proteins, and other biological species on the outermost layers of the sensor.

DISPOSABLE GLUCOSE BIOSENSOR INCLUDING AN ACTIVITY SENSOR

Publication No.:  EP4813291A2 30/09/2026
Applicant: 
VERILY LIFE SCIENCES LLC [US]
DEXCOM INC [US]
Verily Life Sciences LLC
DexCom, Inc.
EP_4813291_PA

Absstract of: EP4813291A2

0001 Example disposable biosensor devices having an activity sensor are disclosed. One example device includes a disposable biosensor that has a first electrode having a distal end to be inserted into a subcutaneous layer beneath a person's skin, the first electrode having a reactive material disposed on the distal end, and a second electrode. The disposable biosensor device also includes an activity sensor that can be activated upon an activity by the person, the activity sensor for detecting the activity and providing data about the activity. The disposable biosensor also includes a radio frequency transmitter for transmitting data obtained from the first or second electrode and the activity sensor.

METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR CGM-BASED PREVENTION OF HYPOGLYCEMIA VIA HYPOGLYCEMIA RISK ASSESSMENT AND SMOOTH REDUCTION INSULIN DELIVERY

Publication No.:  EP4814986A2 30/09/2026
Applicant: 
UNIV VIRGINIA PATENT FOUNDATION [US]
University Of Virginia Patent Foundation
EP_4814986_PA

Absstract of: EP4814986A2

0001 An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.

ASSESSMENT OF PAST INSULIN DELIVERY OUTCOMES TO AUTOMATICALLY TUNE MDA SYSTEMS

Publication No.:  EP4814980A2 30/09/2026
Applicant: 
INSULET CORP [US]
Insulet Corporation
EP_4814980_PA

Absstract of: EP4814980A2

Disclosed are techniques, devices and systems that obtain a glucose measurement history and a liquid drug delivery history. An expected drug delivery amount may be calculated based on the obtained glucose measurement history and the obtained liquid drug delivery history. A processor may calculate a plurality of respective drug delivery amounts implemented using different advisory mode algorithms. A respective advisory drug delivery amount of the plurality of respective advisory drug delivery amounts may be selected by the processor. A recommendation may be generated based on the selected respective advisory drug delivery amount.

Cerebrospinal fluid nasal leakage identification nasal mask dressing

Publication No.:  CN224806666U 29/09/2026
Applicant: 
AFFILIATED TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE OF HUAZHONG UNIV SCI & TECH
\u534E\u4E2D\u79D1\u6280\u5927\u5B66\u540C\u6D4E\u533B\u5B66\u9662\u9644\u5C5E\u540C\u6D4E\u533B\u9662
CN_224806666_U

Absstract of: CN224806666U

The utility model is applicable to the technical field of medical consumables, and provides a cerebrospinal fluid nasal leakage identification nasal mask dressing, which comprises a mask body and ear belts, a window is arranged at the central position of the mask body, a transparent film is fixed on the outer side of the window, seepage absorption cotton is arranged on the inner side of the window, and display test paper is arranged on the lower edge between the transparent film and the seepage absorption cotton. In the structure, the seepage absorption cotton and the display test paper are closely arranged and located on the lower edge, nasal cavity liquid absorbed by the seepage absorption cotton can be transmitted to the display test paper to be absorbed, and as the cerebrospinal fluid contains glucose and the nasal discharge does not contain glucose, whether the seepage contains the cerebrospinal fluid or not can be judged according to the color development condition of the display test paper; therefore, whether the possibility of cerebrospinal fluid nasal leakage exists or not is judged clinically, and a correct clinical decision is made early. The whole product is hung on the ear in a nose mask form, the problems that an existing adhesive tape is unstable in pasting and the face is allergic to the fixing adhesive tape can be solved, meanwhile, the nasal cavity exudation amount can be observed conveniently through the design of the transparent film in the center of the n

Methods of manufacturing electrochemical sensors

Publication No.:  US12745932B1 29/09/2026
Applicant: 
WILLOW LABORATORIES INC [US]
Willow Laboratories, Inc.
US_12745932_B1

Absstract of: US12745932B1

An electrode system for an electrochemical sensor, such as a glucose sensor, is disclosed. The electrode system may include a working electrode, a reference electrode, and a counter electrode. The working electrode may comprise two layers of different metals, such as gold and platinum. A method for forming such an electrode system is disclosed.

Treatment tray for insulin injection

Publication No.:  CN224806803U 29/09/2026
Applicant: 
GUANGDONG SECOND RONGJUN YOUFU HOSPITAL
\u5E7F\u4E1C\u7701\u7B2C\u4E8C\u8363\u519B\u4F18\u629A\u533B\u9662
CN_224806803_U

Absstract of: CN224806803U

The utility model discloses a treatment tray for insulin injection, and belongs to the technical field of insulin injection. The device comprises a first storage box which is rotatably provided with a connecting rod and is provided with a limiting block; the connecting rod is rotationally connected with the second storage box; the sharp instrument box is provided with an opening, a plurality of teeth are arranged on one side of the opening side by side, and a plurality of first rollers are arranged on the other side of the opening side by side. When the insulin pen is used, the needle head is inserted towards one end of the opening and slides to the other end of the opening, the needle head can be driven to rotate relative to the insulin pen under the resistance action of the teeth, so that the needle head is screwed out of the end of the insulin pen, the needle head falls into a sharp instrument box due to the gravity action after being screwed out, and medical staff do not need to unscrew the needle head with hands. And when the needle head is unscrewed through the teeth, the needle head faces the interior of the sharp instrument box, so that the situation that the needle head accidentally hurts medical staff in the screwing-out process can be prevented, the safety is improved, the structure is simple, no extra power element is needed, the cost is low, and the economical efficiency is good.

Hybrides Aufmerksamkeitssystem für die genaue kontinuierliche Echtzeit-Blutzuckermessung bei Diabetes

Publication No.:  DE202026105272U1 28/09/2026
Applicant: 
MATHUR ARCHANA [IN]
MUDIREDDY DHEERAJ REDDY [IN]
NGENZI ALEXANDER [RW]
NITTE MEENAKSHI INST OF TECHNOLOGY NITTE DEEMED TO BE UNIVERSITY [IN]
VIANNEY NYIRIMANA JEAN MARIE [RW]
Mathur, Archana
Mudireddy, Dheeraj Reddy
Ngenzi, Alexander
Nitte Meenakshi Institute of Technology, Nitte (Deemed to be University)
Vianney, Nyirimana Jean Marie

Absstract of: DE202026105272U1

Ein hybrides Aufmerksamkeitssystem zur präzisen, kontinuierlichen Blutzuckermessung in Echtzeit bei Diabetes, bestehend aus:eine tragbare Sensoranordnung mit mindestens einem Glukosesensorelement zur kontinuierlichen Erfassung glukoseabhängiger elektrischer Signale aus einem interstitiellen Flüssigkeitsbereich des Benutzers, einer Hautkontaktschnittstelle zur Aufrechterhaltung eines stabilen Kontakts zwischen dem Glukosesensorelement und der Hautoberfläche sowie einem Temperatursensorelement zur Erzeugung von Temperaturmessungen am Messort;eine analoge Signalaufbereitungseinheit, die elektrisch mit der tragbaren Sensoreinheit verbunden ist und so konfiguriert ist, dass sie die glukoseabhängigen elektrischen Signale verstärkt, filtert, kompensiert und stabilisiert, um aufbereitete Sensorsignale zu erzeugen;eine Analog-Digital-Wandlereinheit, die so konfiguriert ist, dass sie die aufbereiteten Messsignale in sequentielle digitale Glukosemesswerte umwandelt;eine Einheit zur Erfassung physiologischer Parameter, die so konfiguriert ist, dass sie physiologische Messungen wie Hauttemperatur, Bewegungsinformationen, Gewebekontaktdruck und perfusionsbezogene Messungen am Messort empfängt;ein Speicher, der so konfiguriert ist, dass er sequentielle Glukosemessproben, physiologische Messwerte, historische Messdatensätze und Kalibrierungsinformationen speichert;ein Merkmalsgenerierungsprozessor, der so konfiguriert ist, dass er zeitliche Merkmalsdarstellungen und physiologische Me

Portable insulin injection positioning auxiliary device

Publication No.:  CN224792675U 25/09/2026
Applicant: 
UNIV JIANGSU
\u6C5F\u82CF\u5927\u5B66
CN_224792675_U

Absstract of: CN224792675U

The utility model relates to the technical field of insulin injection, and provides a portable insulin injection positioning auxiliary device which comprises a main body assembly. The main body assembly comprises a semitransparent flexible silica gel plate and an anti-skid pad. The non-slip mat is fixedly connected to the bottom end of the semitransparent flexible silica gel plate; the auxiliary assembly comprises a rubber strip, a plastic disc, a sliding groove and a sliding block; the rubber strip is fixedly connected to the center of the top of the semitransparent flexible silica gel plate, the sliding groove is formed in the inner side of the rubber strip, the sliding block is slidably connected to the interior of the sliding groove, and the plastic disc is fixedly connected to one side of the sliding block. According to the utility model, through the arrangement of the auxiliary assembly and the auxiliary matching between the rubber strip and the plastic disc, the injection needle tube can be placed above the rubber block, and meanwhile, the rubber block is pushed and then rotated for auxiliary injection, so that a user can be helped to quickly find a proper injection point and ensure that the injection angle is correct; the absorption problem and the skin injury caused by improper injection are reduced.

Methods of treating diabetes

Publication No.:  NZ800826A 25/09/2026
Applicant: 
ELI LILLY AND CO
ELI LILLY AND COMPANY
WO_2022132709_A1

Absstract of: NZ800826A

Described herein are doses and dosing regimens comprising determining and administering doses of long-acting insulin receptor agonists suitable for once-weekly dosing, such as Weekly Basal Insulin-Fc (BIF). In particular, the invention provides the use of insulin efsitora alfa/BIF for treating diabetes comprising an initial 3x loading dose followed by one or more once-weekly maintenance dose/s.

Body attachable unit for continuous blood glucose measurement

Publication No.:  NZ799606A 25/09/2026
Applicant: 
I SENS INC
I-SENS INC.
US_20250090053_PA

Absstract of: NZ799606A

A body-attachable unit for continuous glucose measurement that includes an upper and lower case enclosing a PCB 530, communication chip 540, battery 535, and a sensor unit 520. The sensor unit 520 can be inserted into the body. Initially, the sensor and communication chip are disconnected while the battery 535 remains connected to the PCB 530. Switching to an active state (where sensor and chip are connected) occurs when a user-intended object approaches a specific region of the unit.

Method for calibrating sensitivity for glucose measurement

Publication No.:  NZ813952A 25/09/2026
Applicant: 
I SENS INC
i-SENS Inc.
EP_4512326_PA

Absstract of: NZ813952A

An embodiment may provide a method for calibrating sensitivity for glucose measurement including: obtaining an offset value for determining sensitivity; determining a first sensitivity from a sensor data and a reference glucose value, based on the offset value; and determining sensitivity by adjusting the first sensitivity, wherein the determining of the sensitivity includes obtaining one sensitivity, and determining sensitivity A by adjusting the one sensitivity by reflecting an average sensor data obtained by averaging a plurality of sensor data and an average glucose value obtained by averaging a plurality of glucose values to the one sensitivity; and determining the sensitivity A as the sensitivity.

MEDICAL INFUSION PUMP SYSTEM FOR THE DELIVERY OF AN INSULIN COMPOUND

Publication No.:  ES3079633T3 25/09/2026
Applicant: 
ARECOR LTD
Arecor Limited
WO_2019193351_A1

Absstract of: WO2019193351A1

There is provided inter aliaa medical infusion pump system comprising a pump and a reservoir comprising an aqueous liquid pharmaceutical composition for delivery by means of said pump to a mammal wherein the composition comprises (i) an insulin compound at a concentration of 400 U/mLor more, (ii) ionic zinc and (iii) a non-ionic surfactant and wherein the said pump delivers the composition in pulses wherein the volume of the pulse is 0.5 µLor less.

HEMOGLOBIN CONCENTRATION MEASUREMENT DEVICE, BLOOD GLUCOSE LEVEL MEASUREMENT DEVICE, AND HEMOGLOBIN CONCENTRATION MEASUREMENT METHOD

Publication No.:  WO2026196765A1 24/09/2026
Applicant: 
HAMAMATSU PHOTONICS K K [JP]
\u6D5C\u677E\u30DB\u30C8\u30CB\u30AF\u30B9\u682A\u5F0F\u4F1A\u793E
WO_2026196765_A1

Absstract of: WO2026196765A1

This hemoglobin concentration measurement device comprises: a light output unit that outputs, to a living body, measurement light including at least light having a first wavelength and light having a second wavelength different from the first wavelength; a light detection unit that detects the measurement light transmitted through the living body; a signal acquisition unit that acquires, on the basis of a detection result of the light detection unit, a first signal relating to blood of the living body and a second signal relating to surrounding tissue other than the blood of the living body; and a hemoglobin concentration estimation unit that estimates a hemoglobin concentration on the basis of the first signal and the second signal acquired by the signal acquisition unit when a blood flow state of the living body is a first state, and the first signal and the second signal acquired by the signal acquisition unit when the blood flow state is a second state different from the first state.

PHOTONIC INTERPENETRATING POLYMERIC NETWORK STRUCTURE BASED-GLUCOSE BIOSENSOR, MANUFACTURING METHOD THEREFOR, AND SKIN-ATTACHABLE SWEAT-BASED GLUCOSE BIOSENSOR PATCH COMPRISING SAME

Publication No.:  WO2026197573A1 24/09/2026
Applicant: 
KYUNGPOOK NATIONAL UNIV INDUSTRY ACADEMIC COOPERATION FOUNDATION [KR]
\uACBD\uBD81\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8
WO_2026197573_A1

Absstract of: WO2026197573A1

The present invention relates to: a photonic interpenetrating polymeric network structure-based glucose biosensor in which a cholesteric liquid crystal in a solid state and a cationic polymer electrolyte are combined; a manufacturing method therefor; and a skin-attachable sweat-based glucose biosensor patch comprising same. The photonic interpenetrating polymeric network structure-based glucose biosensor according to the present invention is easy to manufacture, can be manufactured as a film, can be attached to the skin, and can visually detect the glucose concentration in the body quickly and accurately using only a small amount of sweat.

JOINT STATE ESTIMATION PREDICTION THAT EVALUATES DIFFERENCES IN PREDICTED VS. CORRESPONDING RECEIVED DATA

Publication No.:  US20260290595A1 24/09/2026
Applicant: 
DEXCOM INC [US]
Dexcom, Inc.
US_20260290595_A1

Absstract of: US20260290595A1

0000 Systems and methods are provided for reconciling untrusted data of a subject using trusted data pertaining to the subject. Systems and methods are directed to evaluating differences in predicted data with respect to corresponding received data. Systems and methods estimate metabolic states from a combination of trusted and untrusted metabolic inputs, along with optionally using a personalized mathematical model with parameter optimization. Systems and methods provide for reconciled untrusted inputs with their measured impact of the glycemic signals that is consistent with a metabolic model. Estimation of future metabolic states for decision support and automated insulin dosing is enabled. Replay of scenarios with estimated or reconciled data is also provided.

USING CONTINUOUS BIOMETRIC INFORMATION MONITORING FOR SECURITY

Publication No.:  US20260288926A1 24/09/2026
Applicant: 
DEXCOM INC [US]
Dexcom, Inc.
US_20260288926_A1

Absstract of: US20260288926A1

0000 Measurements of biometric information of a user are obtained over time, such as blood glucose measurements. These biometric measurements are typically obtained by a wearable biometric information monitoring device being worn by the user. These biometric measurements are used by various different systems, such as a computing device of the user or a biometric information monitoring platform that receives biometric measurements from multiple different users. The biometric measurements are used for various security aspects, such as one or more of part of multi-factor authentication of the user, generating security keys (e.g., connection keys, encryption keys), identifying biometric measurements associated with different user identifiers but the same use, and protecting biometric measurements so as to be retrievable only by a recipient associated with an additional computing device, and so forth.

INSULIN INFUSION SET

Publication No.:  US20260284305A1 24/09/2026
Applicant: 
TANDEM DIABETES CARE INC [US]
Tandem Diabetes Care, Inc.
US_20260284305_A1

Absstract of: US20260284305A1

0000 Embodiments of devices and methods to maintain preservative concentration in a medication delivered using a medical device are provided. A barrier layer can be used to prevent migration of preservatives. A vent can be used to allow release of preservatives prior to delivery to the patient. An absorbent element can be used to maintain preservative concentration at a desired level. A filter can be used to capture particulates from the medication prior to delivery to a patient.

SYSTEM AND METHOD FOR PREDICTING BLOOD GLUCOSE WITHOUT BLOOD GLUCOSE MEASUREMENTS

Nº publicación: WO2026198676A1 24/09/2026

Applicant:

JANUARY INC [US]
JANUARY, INC.

WO_2026198676_A1

Absstract of: WO2026198676A1

Various systems and methods are disclosed, which may implement a neural network to process a profile of a subject, time-dependent food consumption data of the subject, and time- dependent physical activity data of the subject, to predict a time-dependent blood glucose level of the subject, without measuring blood glucose levels from blood, interstitial fluid, or sweat of the subject.

traducir